Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 401–500 of 679
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
“Drugs of Abuse” as “New Antidepressants”: - Medical and Philosophical Considerations in Treatment
Park, S.-Y., An, Y., & Kang, U. G. (2022) · 신경정신의학 · doi:10.4306/jknpa.2022.61.4.254 · Cited by 1
Therapiemöglichkeiten der Depression nach Non-Response: Ein Update für die Praxis
Walter, H., Haaf, R., & Köhler, S. (2023) · Nervenheilkunde · doi:10.1055/a-2103-7920 · Cited by 1
Zambrano, J., Hernández, J. L. V., Rigal, F. F. B., de la Serna, L. D. A., KANEVSKY, G. A., & Perocco, S. (2023) · Archivos de Neurociencias · doi:10.31157/an.v1iinpress.634 · Cited by 1
Ketamin und Esketamin: Antidepressive pharmakologische Effekte und augmentierte Psychotherapie
Schüle, C., Koller, G., & Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2309-6457 · Cited by 1
Ketamine in Treatment-Resistant Depression
Iqbal, S., Patel, R., Barlas, Z., Safavi, R., McDeavitt, K., & Shah, A. A. (2024) · Psychiatric Annals · doi:10.3928/00485713-20240613-01 · Cited by 1
Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression
Kundert, C. F., Sobule, R., & Ithman, M. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000036 · Cited by 1
El valor del medicamento desde una perspectiva social 2024
(2024) · Fundación Weber eBooks · doi:10.37666/l27-2024 · Cited by 1
Czora-Poczwardowska, K., Kujawski, R., Jaworska, J., Mikołajczak, P. Ł., & Szulc, M. (2024) · Pharmacotherapy in Psychiatry and Neurology · doi:10.5114/fpn.2024.147494 · Cited by 1
Türkmen, C., Boesjes, R., Zandbergen, A.-F., Kamphuis, J., Viechtbauer, W., Schoevers, R. A., & van Dalfsen, J. H. (2025) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.25.1271 · Cited by 1
Vinarcsik, L., Smoller, C., & Grossberg, G. T. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01221-5 · Cited by 1
Rodrigues, J. M. G. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Włodarczyk, A., Cubała, W. J., Gałuszko‐Węgielnik, M., & Wiglusz, M. S. (2021) · doi:10.21203/rs.3.rs-42473/v2 · Cited by 1
Chaïb, S. (2023) · theses.fr (ABES) · doi:10.70675/00e3b294z3b0az4a32zb1c5z3c09edd92416 · Cited by 1
Comparative Efficacy of Ketamine in Treatment-Resistant Depression
Kurt, H. G., Altinay, M. I., & Anand, A. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200113-01
David, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.04.026
The role of Ketamine and Enantiomers in depression: comprehensive clinical review
de Figueiredo, R. H. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/8fbb-w268
Björkholm, C., Gannedahl, A., Levál, A., Rive, B., Cars, T., Själin, M., Sanden, S. V., Hellner, C., & Lundberg, J. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.197
Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
Novel therapeutic drug targets for bipolar disorder
Rosenblat, J. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00037-5
New Pharmacological Therapeutic Approaches for Depressive Disorders: A Systematic Review
de Aquino, T. L., Libório, J. R., Bezerra, A. L. M. S., Cavalcante, G. M. E., Fern, D., Duarte, A. B., Martin, A. L. D. A. R., de Paula, J. D. A., & Neto, M. L. R. (2021) · Archives of Medicine · doi:10.36648/1989-5216.21.13.32
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
The high-pressure structures and properties of τ-Zr(HPO4)2Preprint
Andersen, A. M. K., & Carlson, S. (2004)
Borentain, S., Williamson, D., Turkoz, I., Popova, V., McCall, W. V., Mathews, M., & Wiegand, F. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.347
Khazaal, Y., Elowe, J., Klouček, P., Preisig, M., Tadri, M., Vandeleur, C. L., Vandenberghe, F., Verloo, H., Ros, T., & Guntenb, A. V. (2021) · JMIG · doi:10.53738/revmed.2021.17.720-21.0085
Efficacy in the treatment of depressive disorders
de Aquino, T. L., Libório, J. R., Bezerra, A. L. M. S., Cavalcante, G. M. E., Duarte, D. F. B., Martin, A. L. D. A. R., de Paula, J. D. A., & Neto, M. L. R. (2022) · Avanços em Medicina · doi:10.52329/avanmed.38
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0112
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0138
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0145
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0108
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0130
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0122
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0107
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.035
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.015
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0150
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.044
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.001
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.034
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0128
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.089
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.016
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0105
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.049
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.061
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.048
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.019
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0135
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0156
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.066
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0131
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.052
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.031
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0142
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.014
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.075
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.043
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.077
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.063
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.064
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.081
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.078
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0153
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.054
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.037
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0106
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.021
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0124
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.090
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.062
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.020
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.088
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.070
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0103
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.011
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.080
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0154
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.095
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0123
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.094
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.073
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0129
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.098
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.012
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.027
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.036
Włodarczyk, A., Cubała, W. J., Gałuszko‐Węgielnik, M., & Wiglusz, M. S. (2020) · doi:10.21203/rs.3.rs-42473/v1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0147
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.085
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.